EU/3/08/563: Orphan designation for the treatment of traumatic spinal cord injury

Recombinant derivative of C3 transferase

Overview

On 5 September 2008, orphan designation (EU/3/08/563) was granted by the European Commission to Triskel EU Services, United Kingdom, for recombinant derivative of C3 transferase for the treatment of traumatic spinal cord injury.

The sponsorship was transferred to Vertex Pharmaceuticals (U.K.) Limited, United Kingdom, in January 2015.

The sponsor’s address was updated in January 2022.

Key facts

Active substance
Recombinant derivative of C3 transferase
Intented use
Treatment of traumatic spinal cord injury
Orphan designation status
Positive
EU designation number
EU/3/08/563
Date of designation
05/09/2008
Sponsor

Vertex Pharmaceuticals (Ireland) Limited
Unit 49
Northwood Court
Block F2 Santry
Dublin 9
Ireland
E-mail: vertexmedicalinfo@vrtx.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating